A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion

Diagn Microbiol Infect Dis. May-Jun 2001;40(1-2):27-33. doi: 10.1016/s0732-8893(01)00243-7.

Abstract

The in-vitro activity of fluconazole against 46,831 yeast isolates collected over a two-year period from 57 laboratories in 33 countries worldwide was assessed using a disc diffusion method. Candida albicans was the organism isolated most frequently, accounting for 68.6% of the total number of isolates. C. glabrata, C. tropicalis, C parapsilosis and C. krusei and Cryptococcus neoformans represented 9.9, 4.7, 4.3, 1.9, and 1.4% of isolates respectively during the 2 year period and rates varied markedly between countries. In 1999 data blood isolates represented 4.9% of all isolates and intensive care unit isolates represented 9.9%. In both the 1998 and 1999 data, 99% of C. albicans were fully susceptible (S) to fluconazole, and 95.6% of all species of yeasts tested were S or susceptible-dose dependent (S-DD) to fluconazole. No emerging trends of resistance were noted with any of the Candida spp. tested as 96% of all isolates retained susceptibility (S or S-DD) to this agent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Candida / classification
  • Candida / drug effects*
  • Candidiasis / epidemiology*
  • Candidiasis / microbiology
  • Fluconazole / pharmacology*
  • Global Health*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Population Surveillance*

Substances

  • Antifungal Agents
  • Fluconazole